Alizé Pharma SAS, an Alizé Pharma group company specialised in the development of biopharmaceuticals to treat metabolic disorders and rare diseases, will present the results from two Phase I clinical trials with its unacylated ghrelin analog AZP-531 during the 75th Scientific Sessions of the American Diabetes Association (ADA) in Boston on 5-9 June.
Detailed data will be presented from the two Phase I trials conducted in 76 healthy volunteers and overweight or obese subjects. Top-line data released at the end of 2014 indicated a good safety profile, a pharmacokinetic profile consistent with once-a-day administration and positive effects on glucose control and on body weight of obese subjects.
"This clinical data clearly illustrates the therapeutic potential of AZP-531, combining insulin sensitization and weight reduction, therefore supporting further developments in type 2 diabetes and other metabolic indications," said Thierry Abribat, manager of TAB Consulting and president of Alizé Pharma SAS. "Based on these positive results, we are currently conducting two new clinical trials in type 2 diabetes and in Prader-Willi syndrome. We look forward to releasing new data in the next few months."
The ADA Scientific Sessions bring together over 14,000 participants with a global presence from 124 countries for five days of symposia, oral abstract sessions, interest group discussions, meet-the-expert sessions, and special lectures and addresses.
